| INTRODUC TI ON
Ovarian cancer remains the leading cause of cancer death among gynecological malignancies and is generally diagnosed at an advanced stage with peritoneal or distal metastasis. Treatments for advanced cases mainly involve debulking surgery and platinum/taxane-based chemotherapy;
1 however, the long-term prognosis of patients has not satisfactorily improved over the past decade, and the 5-year survival rate of advanced stage patients is approximately 25%-30%. Therefore, novel therapeutic strategies are urgently needed to further prolong the survival of patients with this disease.
The immune system plays an important role in controlling cancer;
however, tumors escape host immune surveillance using multiple mechanisms. [3] [4] [5] [6] This acquisition of immune tolerance is essential for cancer growth and progression and may be the cause of resistance against conventional cancer immunotherapy. Thus, considerable attention has been paid to the development of treatment modalities to overcome these immune resistance mechanisms in many types of cancers, including ovarian cancer.
7
Programmed cell death ligand 1 (PD-L1) is a member of the B7 family (also known as CD274) and is expressed in a broad range of malignant tumors, as well as in the human tonsils, placental syncytiotrophoblasts, monocytes and lungs. PD-L1 generates an inhibitory signal toward the receptor-mediated activation of T lymphocytes (T cells) by binding to its receptor PD-1 expressed on the surface of activated T cells. 8, 9 Recent studies demonstrated that the PD-L1
and PD-1 signal attenuates local tumor immunity, and this immunosuppressive co-signal (immune checkpoint) may be one of the most important components of the mechanism responsible for tumor immune tolerance. [10] [11] [12] Several clinical trials on immune checkpoint inhibitors, such as the anti-PD-1 antibody and anti-PD-L1 antibody, have achieved significant anti-tumor effects in patients with certain solid tumors and are already clinically applicable for patients with melanoma and non-small-cell lung cancer. These drugs are promising treatments for other solid tumors including ovarian cancer.
13
In ovarian cancer, the expression of PD-L1 on tumors is a poor prognostic factor. [14] [15] [16] Furthermore, a recent study demonstrated that PD-L1 on tumor cells promotes the peritoneal dissemination of ovarian cancer through a dysfunction in cytotoxic T cells in mouse models. 15 Clinical trial data on ovarian cancer showed that the response rate of the anti-PD-1 or anti-PD-L1 antibody was 5.9%-20.0%. 12 The expression of PD-L1 on tumors correlates with clinical responses to anti-PD-1 and anti-PD-L1 therapy in some types of cancers 17 but not in ovarian cancer. 18, 19 Thus, while the expression of PD-L1 has an unfavorable prognostic impact, the pathophysiological and therapeutic roles of tumor-derived PD-L1 in the tumor microenvironment of ovarian cancer are still unclear.
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) (CRISPR/Cas9) is a microbial adaptive immune system using RNA-guide nucleases to cleave foreign genetic elements. This system has recently emerged as a powerful tool for genome engineering in various species and may be used for genome editing. 20 The CRISPR/ Cas9 system consists of the Cas9 protein and a site-specific single guide RNA (sgRNA) and may target any genomic site in the form of 20 nucleotides and PAM domains. The Cas9 protein exhibits nuclease activity and induces double-strand breaks (DSB) in any genomic DNA sequence including PAM domains guided by sgRNA. DSB are mainly ligated through the mutagenic nonhomologous end joining process, leading to the complete disruption of the targeted gene.
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The function of PD-L1 on tumor cells has been evaluated in several types of cancer through the technique of RNA interference (RNAi). 15, 22 However, the knockdown of target gene expression by
RNAi is generally incomplete and temporary. Therefore, in the present study, we evaluated the pathophysiological and immunological roles of cancer cell-derived PD-L1 in the tumor microenvironment using PD-L1 knockout (KO) ovarian cancer cells by the CRISPR/ Cas9-mediated genomic editing technique and attempted to clarify the therapeutic impact of PD-L1 gene disruption on ovarian cancer progression using a mouse model.
| MATERIAL AND ME THODS

| Regents and antibodies
Recombinant murine interferon (IFN)-γ was purchased from PeproTech (Rocky Hill, NJ, USA 
| Cell line and culture
The mouse ovarian carcinoma cell line, ID8, was kindly gifted from Dr Kathy Roby (University of Kansas Medical Center). The cell line was cultured in MEM-alpha (Life Technologies, Carlsbad, CA, USA)
CRISPR/Cas9, genome editing, ovarian cancer, PD-L1, tumor immunity supplemented with 10% FBS, penicillin, streptomycin and amphotericin B (Life Technologies).
| Mice
Specific pathogen-free 8-week-old female C57BL/6 (B6) mice were purchased from Japan SLC (Shizuoka, Japan objective. The distance between the 2 edges of the wound was measured quantitatively at 10 random sites in each image.
| Tumor formation in vivo
To evaluate the effects of PD-L1 KO on tumor progression and survival, a mouse ovarian cancer peritoneal dissemination model was used as reported previously. and 51 according to the protocol for their administration dose and schedule as previously reported. 25 The disseminated tumor weight was measured at the indicated time and was compared with those in PD-L1 KO ID8-inoculated mice. Mice were killed before reaching the moribund state.
| Flow cytometry
The expression of PD-L1 was assessed by flow cytometry. Cells or GAPDH (dilution 1:5000). After the incubation with the HRPconjugated secondary antibody, specific proteins were visualized using chemiluminescence detection (EZ West Lumi; ATTO, Tokyo, Japan).
| Western blotting
| Real-time RT-PCR
Total RNA was extracted using ISOGEN II (Nippon Gene, Tokyo, Japan). One microgram of total RNA was reverse transcribed into cDNA at 37°C for 15 minutes using the Prime-Script RT Reagent Kit with gDNA Eraser (Takara Bio, Shiga, Japan). Generated cDNA was then subjected to a real-time PCR analysis using the SYBR Premix Ex
Taq II Kit (Takara Bio) with specific primer sets ( Table 1 ). The amplification and detection of mRNA were performed using the Thermal
Cycler Dice Real Time System (Takara Bio) according to the manufacturer's instructions. The relative quantity of target gene expression to the β-actin gene was measured using the comparative Ct method as described previously. 
| ELISA
In the intraperitoneal dissemination model, ascites was collected 70 days after the tumor cell injection. Ascites was centrifuged at 9 00 g for 10 minutes, and the supernatant was subjected to ELISA. 
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| Immunohistochemical analyses
Tumor samples were fixed in 4% paraformaldehyde, and paraffinembedded specimens were cut into 4-μm-thick sections.
Deparaffinized sections were immersed in 3% H 2 O 2 to eliminate endogenous peroxidase activity. 
| Double-color immunofluorescence analyses
A double-color immunofluorescence analysis was performed as previously reported. 
| Statistical analyses
Means and SEM were calculated and presented for all parameters examined in the present study. The significance of differences was evaluated using Student's t test or Dunnett's test. The survival time was analyzed using Kaplan-Meier curves, and the log-rank test by JMP Pro (Ver. 13). P < .05 was accepted as being significant. 
| RE SULTS
| Effects of programmed cell death ligand 1 disruption on intratumoral lymphocyte infiltration in a mouse peritoneal dissemination model
To elucidate the mechanism by which the disruption of PD-L1 suppresses ovarian cancer progression, immunohistochemical analyses were performed, and tumor-infiltrating lymphocyte profiling was performed. The numbers of intratumoral CD4 + T cells, CD8 + T cells and CD49 + NK cells were significantly higher in the PD-L1-KO ID8 groups than in their control groups ( Figure 5A , B, C). In contrast, the number of Foxp3 + regulatory T cells was significantly lower in the PD-L1-KO ID8-inoculated groups than in their control groups ( Figure 5D ). No significant differences were observed in the numbers of F4/80 + macrophages between the PD-L1-KO ID8-inoculated groups and their control groups ( Figure 5E ). In addition, the number of PD-1 + immune cells in the tumor microenvironment was significantly higher in the PD-L1-KO ID8 groups than in their control groups ( Figure 5F ). 
| The identification of macrophage subsets in tumor tissues
| Cytokine and chemokine levels in tumors and ascites of mice transplanted with programmed cell death ligand 1 deletion tumor cells
To investigate the mechanisms underlying PD-L1 disruption- 
| D ISCUSS I ON
In the present study, we established a PD-L1 KO ovarian cancer In contrast, PD-L1 on melanoma cells had no significant effect on antitumor immunity. 28 In the present study, we clearly demonstrated that survival times were significantly longer, and tumor weights and ascites were significantly lower in PD-L1-KO ID8-inoculated mice using PD-L1 disrupted ovarian cancer cells by CRISPR/Cas9-mediated ge- growth, metastasis and angiogenesis in cancer. 38 These chemokines F I G U R E 4 Effects of programmed cell death ligand 1 (PD-L1) disruption on mouse survival and tumor dissemination. A, Kaplan-Meier curves and the log-rank test in an overall survival analysis of PD-L1-KO1, KO2, KO3 ID8 and control ID8 cell-inoculated mice (each group, n = 8); ***P < .001. B Kaplan-Meier curves and the log-rank test in an overall survival analysis of PD-L1-KO2 ID8-inoculated and control ID8-inoculated mice treated with cisplatin (each group, n = 7); **P < .01. C, Photograph of peritoneal dissemination and ascites from PD-L1-KO2 ID8-inoculated and control ID8-inoculated mice on day 70. Yellow arrowheads: disseminated tumors on the peritoneum and omentum. Representative results from 6 independent mice in each group are shown. D, The weights of intraperitoneal tumors and ascites volumes were measured in PD-L1-KO2 ID8-inoculated and control ID8 cell-inoculated mice on day 70. All values represent the mean ± SE (n = 6). Statistical significance determined by Student's t test; **P < .01, ***P < .001. E, Photograph of peritoneal dissemination from control ID8-inoculated mice treated with the control isotype-matched IgG antibody, control ID8-inoculated mice treated with the anti-PD-L1 antibody, and the PD-L1 KO2 ID8-inoculated mice on day 70. Yellow arrowheads: disseminated tumors on the peritoneum and omentum. F, The weights of intraperitoneal tumors were measured in the control ID8-inoculated group treated with the control IgG antibody, the control ID8-inoculated group treated with the anti-PD-L1 antibody, and the PD-L1 KO2 ID8-inoculated group on day 70. All values represent the mean ± SE (n = 7 to 8). Statistical significance determined by Student's t test; *P < .05, ***P < .001
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F I G U R E 5 Programmed cell death ligand 1 (PD-L1) disruption in tumors promotes anti-tumor immunity by increasing tumor-infiltrating lymphocytes. 39 and previous studies demonstrated that CXCL1 and CXCL2 were increased in ovarian cancer. 38, 40 This mechanism may support tumor progression being suppressed in our study as a result of an altered macrophage subset from M2 macrophages producing CXCL1 and CXCL2 to M1 macrophages.
The clinical application of CRISPR/Cas9-mediated genome editing targeting tumor cells themselves for cancer gene therapy is still limited because its delivery system into tumors in vivo is challenging. Gene delivery vectors based on adeno-associated virus (AAV) have been utilized in cancer gene therapy because of F I G U R E 7 Cytokine and chemokine expression in disseminated tumors. The gene expression of cytokines and chemokines in peritoneally disseminated tumors from programmed cell death ligand 1 (PD-L1) KO ID8-inoculated and control ID8-inoculated mice was examined by real-time RT-PCR. All values represent the mean ± SE (n = 6). Statistical significance determined by Student's t test; *P < .05, **P < .01, ***P < .001 their safety and efficacy. 41, 42 Recently, some gene therapy models using the AAV of the CRISPR/Cas9 system were reported. 43, 44 The In conclusion, we herein demonstrated that CRISPR/Cas9-mediated PD-L1 disruption on tumor cells promoted anti-tumor immunity by increasing tumor-infiltrating lymphocytes as well as modulating cytokine and chemokine production, and suppressed ovarian cancer progression. These results suggest that PD-L1-targeted therapy by genome editing may be a novel therapeutic strategy for ovarian cancer. 
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Kazuhiko Ino https://orcid.org/0000-0002-6198-0730 F I G U R E 8 Cytokine levels in ascites from ovarian cancer-inoculated mice. Cytokine protein levels in ascites from programmed cell death ligand 1 (PD-L1) KO ID8-and control ID8-inoculated mice were examined by ELISA. All values represent the mean ± SE (n = 6). Statistical significance determined by Student's t test; *P < .05, **P < .01
